Amit Chunilal Nathwani
Fondatore presso Freeline Therapeutics Ltd.
Posizioni attive di Amit Chunilal Nathwani
Società | Posizione | Inizio | Fine |
---|---|---|---|
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | 01/01/2015 | - |
Direttore Tecnico/Scientifico/R&S | 01/01/2015 | - | |
Fondatore | 01/01/2015 | - | |
University College London | Corporate Officer/Principal | 01/11/2011 | - |
Royal Free Hospital Medical School | Corporate Officer/Principal | 01/11/2012 | - |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Direttore/Membro del Consiglio | - | - |
Amministratore Delegato | - | - | |
Fondatore | 01/01/2019 | - |
Storia della carriera di Amit Chunilal Nathwani
Precedenti posizioni note di Amit Chunilal Nathwani
Società | Posizione | Inizio | Fine |
---|---|---|---|
FREELINE THERAPEUTICS HOLDINGS PLC | Direttore/Membro del Consiglio | 26/06/2020 | 04/04/2023 |
Direttore Tecnico/Scientifico/R&S | 20/08/2021 | 01/03/2022 | |
Fondatore | 01/01/2015 | 04/04/2023 | |
Independent Dir/Board Member | 03/04/2020 | 04/04/2023 |
Formazione di Amit Chunilal Nathwani
The Open University | Doctorate Degree |
University of Aberdeen | Undergraduate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 8 |
Posizioni
Director/Board Member | 3 |
Founder | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Settori
Consumer Services | 5 |
Health Technology | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 3 |
---|---|
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Freeline Therapeutics Holdings Plc
Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |